Sunday, July 7, 2019

Late Effects of Treatment for Childhood Cancer (PDQ®)—Health Professional Version - National Cancer Institute 7/10

Late Effects of Treatment for Childhood Cancer (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version

Late Effects of the Immune System

Late effects of the immune system have not been well studied, especially in survivors treated with contemporary therapies. Reports published about long-term immune system outcomes are limited by retrospective data collection, small sample size, cohort selection and participation bias, heterogeneity in treatment approach, time since treatment, and method of ascertainment.

Asplenia

Surgical or functional splenectomy increases the risk of life-threatening invasive bacterial infection:[1]
  • Although staging laparotomy is no longer standard practice for pediatric Hodgkin lymphoma, patients from earlier treatment periods have ongoing risks.[2,3]
  • Children may be rendered asplenic by radiation therapy to the spleen in doses greater than 30 Gy.[4,5] Low-dose involved-field radiation therapy (21 Gy) combined with multiagent chemotherapy did not appear to adversely affect splenic function, as measured by pitted red blood cell assays.[5] No other studies of immune status after radiation therapy are available.
  • Functional asplenia (with Howell-Jolly bodies, reduced splenic size and blood flow) after hematopoietic stem cell transplantation (HSCT) has been attributed to graft-versus-host disease (GVHD).
  • Childhood Cancer Survivor Study investigators observed a significantly increased risk of late infection-related mortality among survivors who were treated with splenectomy (relative risk [RR], 7.7; 95% confidence interval [CI], 3.1–19.1). Splenic radiation was also associated with a dose-related risk of late infection-related mortality (0.1–9.9 Gy: RR, 2.0; 95% CI, 0.9–4.5; 10.0–19.9 Gy: RR, 5.5; 95% CI, 1.9–15.4; >20.0 Gy: RR, 6.0; 95% CI, 1.8–20.2). However, the low cumulative incidence of infection-related late mortality of 1.5% at 35 years after splenectomy and 0.6% after splenic radiation indicates that these are rare events.[6] These data underscore the importance of counseling at-risk survivors about immunizations and other measures to reduce infection risk.
Individuals with asplenia, regardless of the reason for the asplenic state, have an increased risk of fulminant bacteremia, especially associated with encapsulated bacteria, which is associated with a high mortality rate. The risk of bacteremia is higher in younger children than in older children, and this risk may be higher during the years immediately after splenectomy. Fulminant septicemia, however, has been reported in adults up to 25 years after splenectomy.
Bacteremia may be caused by the following organisms in asplenic survivors:
  • Streptococcus pneumoniae. The most common pathogen that causes bacteremia in children with asplenia.
  • Other streptococci.
  • Haemophilus influenzae type b (Hib).
  • Neisseria meningitidis.
  • Escherichia coli; Staphylococcus aureus.
  • Gram-negative bacilli, such as the Salmonella species, the Klebsiella species, and Pseudomonas aeruginosa.
Individuals with functional or surgical asplenia are also at increased risk of fatal malaria and severe babesiosis.

Posttherapy management

Clinicians should consider and encourage the administration of inactivated vaccines (e.g., influenza) and vaccines made of purified antigens (e.g., pneumococcus), bacterial components (e.g., diphtheria-tetanus-pertussis), or genetically engineered recombinant antigens (e.g., hepatitis B) in all cancer and transplant survivors according to recommended doses and schedules.[7-9]
Two primary doses of quadrivalent meningococcal conjugate vaccine should be administered 2 months apart to children with asplenia, from age 2 years through adolescence, and a booster dose should be administered every 5 years.[10] (Refer to the Immunization Schedules for 2019 section of the Red Book for more information.) However, the efficacy of meningococcal vaccines in children with asplenia has not been established. (Refer to the Meningococcal Infections section of the Red Book for more information.) No known contraindication exists to giving these vaccines at the same time as other required vaccines, in separate syringes, at different sites.
Pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV) are indicated at the recommended age for all children with asplenia. Following the administration of the appropriate number of doses of PCV13, PPSV23 should be administered starting at age 24 months. A second dose should be administered 5 years later. For children aged 2 to 5 years with a complete PCV7 series who have not received PCV13, a supplemental dose of PCV13 should be administered. For asplenic individuals aged 6 to 18 years who have not received a dose of PCV13, a supplemental dose of PCV13 should be considered.[11,12] (Refer to the Pneumococcal Infections section of the Red Book for more information.) Hib immunization should be initiated at age 2 months, as recommended for otherwise healthy young children and for previously unimmunized children with asplenia.[11] (Refer to the Immunization Schedules for 2019 section of the Red Book for more information.)
Daily antimicrobial prophylaxis against pneumococcal infections is recommended for young children with asplenia, regardless of their immunization status. Although the efficacy of daily antimicrobial prophylaxis has been proven only in patients with sickle cell anemia, this experience has been extended to other high-risk children, including asplenic children with a history of malignant neoplasms or thalassemia. In general, antimicrobial prophylaxis (in addition to immunization) should be considered for all children with asplenia younger than 5 years and for at least 1 year after splenectomy.
The age at which antimicrobial prophylaxis is discontinued is an empiric decision. On the basis of a multicenter study in sickle cell disease, prophylactic penicillin can be discontinued at age 5 years among those who are receiving regular medical attention and who have not had a severe pneumococcal infection or surgical splenectomy. The appropriate duration of prophylaxis is unknown for children with asplenia attributable to other causes. Some experts continue prophylaxis throughout childhood and into adulthood for particularly high-risk patients with asplenia.
Table 12 summarizes spleen late effects and the related health screenings.
Table 12. Spleen Late Effectsa
Predisposing TherapyImmunologic EffectsHealth Screening/Interventions
GVHD = graft-versus-host disease; HSCT = hematopoietic stem cell transplantation; IgA = immunoglobulin A; T = temperature.
aAdapted from the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers.
Radiation impacting spleen; splenectomy; HSCT with currently active GVHDAsplenia/hyposplenia; overwhelming post-splenectomy sepsisBlood cultures during febrile episodes (T >38.5°C); empiric antibiotics
Immunization for encapsulated organisms (pneumococcal, Haemophilus influenzae type b, and meningococcal vaccines)
HSCT with any history of chronic GVHDImmunologic complications (secretory IgA deficiency, hypogammaglobulinemia, decreased B cells, T cell dysfunction, chronic infections [e.g., conjunctivitis, sinusitis, and bronchitis associated with chronic GVHD])History: chronic conjunctivitis, chronic sinusitis, chronic bronchitis, recurrent or unusual infections, sepsis
Exam: attention to eyes, nose/sinuses, and lungs
Refer to the Centers for Disease Control and Prevention (CDC) Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients for more information on posttransplant immunization.

Humoral Immunity

Although the immune system appears to recover from the effects of active chemotherapy and radiation therapy, there is some evidence that lymphoid subsets do not normalize in all survivors. Innate immunity, thymopoiesis, and DNA damage responses to radiation were shown to be abnormal in survivors of childhood leukemia.[13] Defects in immune recovery characterized by B-cell depletion have been observed in 2-year survivors of standard-risk and intermediate-risk acute lymphoblastic leukemia (ALL).[14] Antibody levels to previous vaccinations are also reduced in patients off therapy for ALL for at least 1 year,[15,16] suggesting abnormal humoral immunity [17] and a need for revaccination in such children. Survivors of childhood cancer may remain susceptible to vaccine-preventable infections. Treatment intensity, age at diagnosis, and time from treatment are associated with the risk of losing pre-existing immunity.[18,19]
While there is a paucity of data regarding the benefits of administering active immunizations in this population, reimmunization is necessary to provide protective antibodies. The recommended reimmunization schedule will depend on previously received vaccinations and on the intensity of therapy.[20,21] In some children who received intensive treatment, consideration may be given to evaluating the antibodies against common vaccination antigens to determine the need for revaccination. (Refer to the Immunization Schedules for 2019 section of the Red Book for more information.)
Immune status is also compromised after HSCT, particularly in association with GVHD.[22] In a prospective, longitudinal study of 210 survivors treated with allogeneic HSCT, antibody responses lasting for more than 5 years after immunization were observed in most patients for tetanus (95.7%), rubella (92.3%), poliovirus (97.9%), and, in diphtheria-tetanus-acellular pertussis (DTaP) recipients, diphtheria (100%). However, responses to pertussis (25.0%), measles (66.7%), mumps (61.5%), hepatitis B (72.9%), and diphtheria in tetanus-diphtheria (Td) recipients (48.6%) were less favorable. Factors associated with vaccine failure include older age at immunization; lower CD3, CD4, or CD19 count; higher immunoglobulin M concentration; positive recipient cytomegalovirus serology; negative titer before immunization; history of acute or chronic GVHD; and radiation conditioning.[23]
Follow-up recommendations for transplant recipients have been published by the major North American and European transplant groups, the CDC, and the Infectious Diseases Society of America.[24,25]
Refer to the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers for immune system late effects information including risk factors, evaluation, and health counseling.
References
  1. Immunization in special circumstances. In: Kimberlin DW, Brady MT, Jackson MA, et al., eds.: Red Book: 2018–2021 Report of the Committee on Infectious Diseases. 31st ed. Itasca, Ill: American Academy of Pediatrics, 2018, pp 67-111.
  2. Kaiser CW: Complications from staging laparotomy for Hodgkin disease. J Surg Oncol 16 (4): 319-25, 1981. [PUBMED Abstract]
  3. Jockovich M, Mendenhall NP, Sombeck MD, et al.: Long-term complications of laparotomy in Hodgkin's disease. Ann Surg 219 (6): 615-21; discussion 621-4, 1994. [PUBMED Abstract]
  4. Coleman CN, McDougall IR, Dailey MO, et al.: Functional hyposplenia after splenic irradiation for Hodgkin's disease. Ann Intern Med 96 (1): 44-7, 1982. [PUBMED Abstract]
  5. Weiner MA, Landmann RG, DeParedes L, et al.: Vesiculated erythrocytes as a determination of splenic reticuloendothelial function in pediatric patients with Hodgkin's disease. J Pediatr Hematol Oncol 17 (4): 338-41, 1995. [PUBMED Abstract]
  6. Weil BR, Madenci AL, Liu Q, et al.: Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 36 (16): 1571-1578, 2018. [PUBMED Abstract]
  7. National Center for Immunization and Respiratory Diseases: General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 60 (RR02): 1-60, 2011. Available online Last accessed April 17, 2019.
  8. Bridges CB, Coyne-Beasley T; Advisory Committee on Immunization Practices: Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014. Ann Intern Med 160 (3): 190, 2014. [PUBMED Abstract]
  9. Rubin LG, Levin MJ, Ljungman P, et al.: 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58 (3): 309-18, 2014. [PUBMED Abstract]
  10. Centers for Disease Control and Prevention (CDC): Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 60 (40): 1391-2, 2011. [PUBMED Abstract]
  11. Kimberlin DW, Brady MT, Jackson MA, et al., eds.: Red Book: 2018–2021 Report of the Committee on Infectious Diseases. 31st ed. Itasca, Ill: American Academy of Pediatrics, 2018. Also available online. Last accessed April 11, 2019.
  12. Centers for Disease Control and Prevention (CDC): Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 62 (25): 521-4, 2013. [PUBMED Abstract]
  13. Schwartz C L, Hobbie WL, Constine LS, et al., eds.: Survivors of Childhood Cancer: Assessment and Management. St. Louis, Mo: Mosby, 1994.
  14. Koskenvuo M, Ekman I, Saha E, et al.: Immunological Reconstitution in Children After Completing Conventional Chemotherapy of Acute Lymphoblastic Leukemia is Marked by Impaired B-cell Compartment. Pediatr Blood Cancer 63 (9): 1653-6, 2016. [PUBMED Abstract]
  15. Leung W, Neale G, Behm F, et al.: Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol 34 (3): 303-8, 2010. [PUBMED Abstract]
  16. Aytac S, Yalcin SS, Cetin M, et al.: Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol 27 (5): 333-43, 2010. [PUBMED Abstract]
  17. Brodtman DH, Rosenthal DW, Redner A, et al.: Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr 146 (5): 654-61, 2005. [PUBMED Abstract]
  18. Fayea NY, Fouda AE, Kandil SM: Immunization status in childhood cancer survivors: A hidden risk which could be prevented. Pediatr Neonatol 58 (6): 541-545, 2017. [PUBMED Abstract]
  19. Bochennek K, Allwinn R, Langer R, et al.: Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer. Vaccine 32 (27): 3357-61, 2014. [PUBMED Abstract]
  20. Ruggiero A, Battista A, Coccia P, et al.: How to manage vaccinations in children with cancer. Pediatr Blood Cancer 57 (7): 1104-8, 2011. [PUBMED Abstract]
  21. Patel SR, Chisholm JC, Heath PT: Vaccinations in children treated with standard-dose cancer therapy or hematopoietic stem cell transplantation. Pediatr Clin North Am 55 (1): 169-86, xi, 2008. [PUBMED Abstract]
  22. Olkinuora HA, Taskinen MH, Saarinen-Pihkala UM, et al.: Multiple viral infections post-hematopoietic stem cell transplantation are linked to the appearance of chronic GVHD among pediatric recipients of allogeneic grafts. Pediatr Transplant 14 (2): 242-8, 2010. [PUBMED Abstract]
  23. Inaba H, Hartford CM, Pei D, et al.: Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol 156 (1): 109-17, 2012. [PUBMED Abstract]
  24. Rizzo JD, Wingard JR, Tichelli A, et al.: Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 37 (3): 249-61, 2006. [PUBMED Abstract]
  25. Tomblyn M, Chiller T, Einsele H, et al.: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15 (10): 1143-238, 2009. [PUBMED Abstract]

Late Effects of the Musculoskeletal System

The musculoskeletal system of growing children and adolescents is vulnerable to the cytotoxic effects of cancer therapies, including surgery, chemotherapy, and radiation therapy. Documented late effects include the following:
  • Bone and joint (abnormal bone and/or muscle growth) problems.
  • Deformity and functional loss associated with amputation/limb-sparing surgery, joint contracture, osteoporosis/fractures, and osteonecrosis.
  • Changes in body composition (obesity and loss of lean muscle mass).
While these late effects are discussed individually, it is important to remember that the components of the musculoskeletal system are interrelated. For example, hypoplasia to a muscle group can negatively affect the function of the long bones and the resultant dysfunction can subsequently lead to disuse and osteoporosis.
The major strength of the published literature documenting musculoskeletal late effects among children and adolescents treated for cancer is that most studies have clearly defined outcomes and exposures. However, many studies are observational and cross-sectional or retrospective in design. Single-institution studies are common, and for some outcomes, only small convenience cohorts have been described. Thus, it is possible that studies either excluded patients with the most severe musculoskeletal effects because of death or inability to participate in follow-up testing, or oversampled those with the most severe musculoskeletal late effects because these patients were accessible as they returned for complication-related follow-up. Additionally, some of the results reported in adult survivors of childhood cancer may not be relevant to patients currently being treated because the delivery of anticancer modalities, particularly radiation therapy, has changed over the years in response to documented toxicities.[1,2]

Abnormal Bone Growth

The effect of radiation on bone growth depends on the sites irradiated, as follows:

Radiation to the head and brain

In an age- and dose-dependent fashion, radiation can inhibit normal bone and muscle maturation and development. Radiation to the head (e.g., cranial, orbital, infratemporal, or nasopharyngeal radiation therapy) can cause craniofacial abnormalities, particularly in children treated before age 5 years who received radiation doses of 20 Gy or higher [3-8] or who were treated with concomitant chemotherapy.[9] Soft tissue sarcomas such as orbital rhabdomyosarcoma and retinoblastoma are two of the more common cancer types treated with these radiation fields. Often, in addition to the cosmetic impact of the craniofacial abnormalities, there can be related dental and sinus problems.
Cranial radiation therapy damages the hypothalamic-pituitary axis in an age- and dose-response fashion and can result in growth hormone deficiency.[10-13] If the growth hormone deficiency is not treated during the growing years and, sometimes, even with appropriate treatment, it leads to a substantially lower final height. Patients with a central nervous system (CNS) tumor [10,14] or acute lymphoblastic leukemia (ALL) [15-17] treated with 18 Gy or higher of cranial radiation therapy are at highest risk. Patients treated with total-body irradiation (TBI), particularly single-fraction TBI,[18-21] and those treated with cranial radiation for non-CNS solid tumors [22] are also at risk of growth hormone deficiency. If the spine is also irradiated (e.g., craniospinal radiation therapy for medulloblastoma or early ALL therapies in the 1960s), growth can be affected by two separate mechanisms—growth hormone deficiency and direct damage to the spine.

Radiation to the spine and long bones

Radiation therapy can also directly affect the growth of the spine and long bones (and associated muscle groups) and can cause premature closure of the epiphyses, leading to the following:[23-31]
  • Short stature.
  • Asymmetric growth (scoliosis/kyphosis).
  • Limb-length discrepancy.
Orthovoltage radiation therapy, commonly used before 1970, delivered high doses of radiation to bone and was commonly associated with subsequent abnormalities in bone growth. However, even with contemporary radiation therapy, if a solid tumor is located near an epiphysis or the spine, alterations in normal bone development can be difficult to avoid.
The effects of radiation therapy administered to the spine on stature in survivors of Wilms tumor have been assessed.
Evidence (effect of radiation therapy on the spine and long bones):
  1. In the National Wilms Tumor Study (NWTS), studies 1 through 4, stature loss in 2,778 children was evaluated.[24] Repeated height measurements were collected during long-term follow-up. The effects of radiation dosage, age at treatment, and chemotherapy on stature were analyzed using statistical models that accounted for the normal variation in height with sex and advancing age. Predictions from the model were validated by descriptive analysis of heights measured at ages 17 to 18 years for 205 patients.
    • For those younger than 12 months at diagnosis who received more than 10 Gy of radiation therapy, the estimated adult-height deficit was 7.7 cm when compared with the nonradiation therapy group.
    • For those who received 10 Gy, the estimated trunk shortening was 2.8 cm or less.
    • Among those whose height measurements in the teenage years were available, patients who received more than 15 Gy of radiation therapy were 4 to 7 cm shorter on average than their nonirradiated counterparts, with a dose-response relationship evident.
    • Chemotherapy did not confer additional risk.
  2. The effect of radiation therapy on the development of scoliosis has also been re-evaluated. In a group of 42 children treated for Wilms tumor from 1968 to 1994, scoliosis was seen in 18 patients, with only one patient needing orthopedic intervention.[32]
    • Median time to development of scoliosis was 102 months (range, 16–146 months).
    • A clear dose-response relationship was seen; children treated with lower doses (<24 Gy) of radiation had a significantly lower incidence of scoliosis than those who received more than 24 Gy of radiation.
    • There was also a suggestion that the incidence was lower in patients who received 10 to 12 Gy, the dosages currently used for Wilms tumor, although the sample size was small.

Osteoporosis and Fractures

Although increased rates of fracture are not reported among long-term survivors of childhood cancer,[33] maximal peak bone mass is an important factor influencing the risk of osteoporosis and fracture among older patients. Treatment-related factors that affect bone mineral loss include the following:
  • Chemotherapy. Methotrexate has a cytotoxic effect on osteoblasts, resulting in a reduction of bone volume and formation of new bone.[34,35] This effect may be exacerbated by the chronic use of corticosteroids, another class of agents routinely used in the treatment of hematological malignancies and in supportive care for a variety of pediatric cancers.
  • Radiation therapy. Radiation-related endocrinopathies, such as growth hormone deficiency or hypogonadism, may contribute to ongoing bone mineral loss.[36-39]
  • Nutrition and activity. Suboptimal nutrition and physical inactivity may further predispose to deficits in bone mineral accretion.
Most of our knowledge about cancer and treatment effects on bone mineralization has been derived from studies of children with ALL.[34,40] In this group, the leukemic process, and possibly vitamin D deficiency, may play a role in the alterations in bone metabolism and bone mass observed at diagnosis.[41] Antileukemic therapy causes additional bone mineral density loss,[42] which has been reported to normalize over time [43,44] or to persist for many years after completion of therapy.[45,46] Clinical factors predicting higher risk of low bone mineral density include treatment with the following:[38,45,47-49]
  • High cumulative doses of methotrexate (>40 g/m2).
  • High cumulative doses of corticosteroids (>9 g/m2).
  • Cranial radiation therapy or craniospinal radiation therapy.
  • More potent glucocorticoids such as dexamethasone.
The development of osteonecrosis during treatment for ALL also predicts higher risk of low bone density.[50]
Clinical assessment of bone mineral density in adults treated for childhood ALL indicates that most bone mineral deficits normalize over time after discontinuing osteotoxic therapy.
Evidence (low bone mineral density):
  1. A cohort of 845 adult survivors of childhood ALL were evaluated at a median age of 31 years.[38]
    • Very low bone mineral density was relatively uncommon, with only 5.7% and 23.8% of patients demonstrating bone mineral density z-scores consistent with osteoporosis and osteopenia, respectively.
    • Cranial radiation dose of 24 Gy or higher, but not cumulative methotrexate or prednisone equivalent doses, was associated with a twofold elevated risk of bone mineral density z-scores of -1 or lower.
    • In a subset of 400 survivors with longitudinal bone mineral density evaluations, bone mineral density z-scores tended to improve from adolescence to young adulthood.
  2. Among 862 ALL survivors (median age, 31.3 years) evaluated by quantitative computed tomography of L1 through L2 vertebrae, 30% of survivors had low bone mineral density (z-score below -1) and 18.6% met criteria for frailty or prefrailty.[51]
    The prefrail phenotype is characterized by having two of five characteristics (low muscle mass, self-reported exhaustion, low energy expenditure, slow walking speed, and weakness) and the frail phenotype is characterized by having three or more of these characteristics. Modifiable factors such as growth hormone deficiency, smoking, and alcohol consumption were significant predictors for these outcomes, with varying impact on the basis of sex. These data underscore the importance of lifestyle counseling and screening for hormonal deficits during long-term survivors' follow-up evaluations.
Bone mineral density deficits that are likely multifactorial in etiology have been reported in allogeneic hematopoietic stem cell transplantation (HSCT) recipients conditioned with TBI.[52,53] French investigators observed a significant risk of lower femoral bone mineral density among adult survivors of childhood leukemia treated with HSCT who had gonadal deficiency.[54] Hormonal therapy has been shown to enhance the bone mineral density of adolescent girls diagnosed with hypogonadism after HSCT.[55]
Despite disease-related and treatment-related risks of bone mineral density deficits, the prevalence of self-reported fractures among Childhood Cancer Survivor Study (CCSS) participants was lower than that reported by sibling controls. Predictors of increased prevalence of fracture by multivariable analyses included the following:[33]
  • Among female survivors, increasing age at follow-up, white race, methotrexate treatment, and balance difficulties.
  • Among male survivors, smoking history and white race.
Radiation-induced fractures can occur with doses of radiation of 50 Gy or higher, as is often used in the treatment of Ewing sarcoma of the extremity.[56,57]

Osteonecrosis

Osteonecrosis (also known as aseptic or avascular necrosis) is a rare, but well-recognized skeletal complication observed predominantly in survivors of pediatric hematological malignancies treated with corticosteroids.[58-60] The prevalence of osteonecrosis has varied from 1% to 22% based on the study population, treatment protocol, method of evaluation, and time from treatment.[60-66]
The condition is characterized by death of one or more segments of bone that most often affects weight-bearing joints, especially the hips and knees. Longitudinal cohort studies have identified a spectrum of clinical manifestations of osteonecrosis, ranging from asymptomatic, spontaneously-resolving imaging changes to painful progressive articular collapse requiring joint replacement.[67,68] Symptomatic osteonecrosis characterized by pain, joint swelling, and reduced mobility typically presents during the first 2 years of therapy, particularly in patients with ALL. These symptoms may improve over time, persist, or progress in the years after completion of therapy.[69] In one series, 60% of patients continued to have symptoms at a median follow-up of 4.9 years after diagnosis of osteonecrosis.[70] Surgical procedures, including core decompression, osteotomy, and joint replacements, are sometimes performed in those with persistently severe symptoms.[70]
Factors that increase the risk of osteonecrosis include the following:
  • Exposure to corticosteroids and, possibly, methotrexate and concurrent asparaginase. The most important treatment factor associated with the development of osteonecrosis is prolonged exposure to corticosteroids, which is typical in treatment regimens used for ALL, non-Hodgkin lymphoma, and HSCT.[63,66,71,72]
    Osteonecrosis risk may be related to type of corticosteroid, with some studies in patients with ALL indicating increased risk with the use of dexamethasone compared with prednisone.[73,74]
    Corticosteroid dosing schedule also appears to impact the risk of developing osteonecrosis. In the Children’s Oncology Group (COG) 1961 trial for newly diagnosed high-risk ALL, patients were randomly assigned to receive either continuous (daily) dexamethasone or an alternate-week schedule of dexamethasone during the delayed intensification phase; the alternate-week schedule was associated with a lower incidence of osteonecrosis.[60]
    In addition to corticosteroids, exposure to methotrexate and concurrent asparaginase may contribute to the development of osteonecrosis.[75,76]
  • Development of thromboembolism during antileukemic therapy. In a retrospective review of 208 children treated for ALL, investigators at McMaster University reported a 5.21-fold (95% CI, 1.82–14.91) increased odds of osteonecrosis among children who experienced thromboembolism during antileukemic therapy than among those who did not have a thromboembolism, even after accounting for age and asparaginase exposure.[76]
  • HSCT conditioning and course. In a large case-control study that evaluated risk factors for osteonecrosis using data from the Center for International Blood and Marrow Transplant Research, lower risks of osteonecrosis were seen in patients with nonmalignant diseases and in those who had received reduced-intensity conditioning regimens for malignant diseases than were seen in patients receiving myeloablative regimens for malignant diseases.[77] Several studies have reported an increased risk of osteonecrosis in association with chronic graft-versus-host disease (GVHD).[64,71,77]
  • Age at time of diagnosis or transplant. Several studies have demonstrated that age at diagnosis (or at time of transplant) is a significant independent predictor of osteonecrosis.[60,61,66,70,71,73,77] Osteonecrosis is significantly more common in older children and adolescents than in younger children. In the COG-1961 trial for high-risk ALL, the 5-year cumulative incidence of symptomatic osteonecrosis was 1.0% for patients aged 1 to 9 years, 9.9% for patients aged 10 to 15 years, and 20% for patients aged 16 to 21 years (P < .0001).[60]
  • Race. Osteonecrosis also occurs more frequently in white patients than in black patients.[72,78]
  • Genetic factors. Genetic factors influencing folate metabolism, glucocorticoid metabolism, and adipogenesis have been linked to excess risk of osteonecrosis among survivors.[72,79,80]
    • Two candidate gene studies indicate that children homozygous for a 28–base pair repeat within the 5’ untranslated region of the TS gene are at increased risk of osteonecrosis.[72,80] This gene is associated with folate production and replacement and is inhibited by methotrexate.
    • St. Jude Children's Research Hospital investigators observed an almost sixfold (odds ratio, 5.6; 95% confidence interval, 2.7–11.3) risk of osteonecrosis among survivors with polymorphism of the ACP1 gene, which regulates lipid levels and osteoblast differentiation.[65]
    • Genome-wide association studies have identified potential risk variants in BMP7, PROX1-AS1, GRID2 (children younger than 10 years), and GRIN3A, which are all associated with glucocorticoid receptor activity.[79,81]
Studies evaluating the influence of sex on the risk of osteonecrosis have yielded conflicting results, with some suggesting a higher incidence in females [67,70,78] that has not been confirmed by others.[59,67]

Osteochondroma

Osteochondromas are benign boney protrusions that can be spontaneous or associated with radiation therapy. They generally occur as a single lesion; however, multiple lesions may develop in the context of hereditary multiple osteochondromatosis.[82] Approximately 5% of children undergoing myeloablative HSCT will develop osteochondroma, which most commonly presents in the metaphyseal regions of long bones.[82,83]
Evidence (risk of osteochondroma):
  1. A large Italian study reported a 6.1% cumulative risk of developing osteochondroma at 15 years posttransplant, with increased risk associated with younger age at transplant (≤3 years) and use of TBI.[84]
  2. Osteochondromas have been reported in patients with neuroblastoma who received local radiation therapy, anti-GD2 monoclonal antibody therapy, and isotretinoin. [85]
    • Osteochondromas occurred at a median of 8.2 years from diagnosis, and the cumulative incidence rate was 4.9% at 10 years from diagnosis among 362 patients younger than 10 years.
    • In this series, most of the osteochondromas were unrelated to radiation and had features characteristic of benign developmental osteochondroma.
    • The pathogenic role for chemotherapy, anti-GD2 monoclonal antibody therapy, or isotretinoin in the development of osteochondroma remains speculative.
Growth hormone therapy may influence the onset and pace of growth of osteochondromas.[21,86]
Because malignant degeneration of these lesions is exceptionally rare, clinical rather than radiological follow-up is most appropriate.[87] Surgical resection is only necessary when the lesion interferes with joint alignment and movement.[88]

Amputation and Limb-Sparing Surgery

Amputation and limb-sparing surgery prevent local recurrence of bone tumors by removal of all gross and microscopic disease. If optimally executed, both procedures accomplish an en bloc excision of tumor with a margin of normal uninvolved tissue. The type of surgical procedure, the primary tumor site, and the age of the patient affect the risk of postsurgical complications.[40] Complications in survivors treated with amputation include prosthetic fit problems, chronic pain in the residual limb, phantom limb pain, and bone overgrowth.[89,90] While limb-sparing surgeries may offer a more aesthetically pleasing outcome, complications have been reported more frequently in survivors who underwent these procedures than in those treated with amputation. Complications after limb-sparing surgery include non-union, pathologic fracture, aseptic loosening, limb-length discrepancy, endoprosthetic fracture, and limited joint range of motion.[89,91] Occasionally, refractory complications develop after limb-sparing surgery and require amputation.[92,93]
A number of studies have compared functional outcomes after amputation and limb-sparing surgery, but results have been limited by inconsistent methods of functional assessment and small cohort sizes. Overall, data suggest that limb-sparing surgery results in better function than amputation, but differences are relatively modest.[89,93,94] Similarly, long-term quality of life outcomes among survivors undergoing amputation and limb sparing procedures have not differed substantially.[92] A longitudinal analysis of health status among extremity sarcoma survivors in the CCSS indicates an association between lower extremity amputation and increasing activity limitations with age, and an association between upper extremity amputation and lower educational attainment.[95]

Joint Contractures

HSCT with any history of chronic GVHD is associated with joint contractures.[96-98]
Table 13 summarizes bone and joint late effects and the related health screenings.
Table 13. Bone and Joint Late Effectsa
Predisposing TherapyMusculoskeletal EffectsHealth Screening
CT = computed tomography; DXA = dual-energy x-ray absorptiometry; GVHD = graft-versus-host disease; HSCT = hematopoietic stem cell transplantation.
aAdapted from the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers.
Radiation impacting musculoskeletal systemHypoplasia; fibrosis; reduced/uneven growth (scoliosis, kyphosis); limb length discrepancyExam: bones and soft tissues in radiation fields
Radiation impacting head and neckCraniofacial abnormalitiesHistory: psychosocial assessment, with attention to: educational and/or vocational progress, depression, anxiety, posttraumatic stress, social withdrawal
Head and neck exam
Radiation impacting musculoskeletal systemRadiation-induced fractureExam of affected bone
Methotrexate; corticosteroids (dexamethasone, prednisone); radiation impacting skeletal structures; HSCTReduced bone mineral densityBone mineral density test (DXA or quantitative CT)
Corticosteroids (dexamethasone, prednisone)OsteonecrosisHistory: joint pain, swelling, immobility, limited range of motion
Musculoskeletal exam
Radiation with impact to oral cavityOsteoradionecrosisHistory/oral exam: impaired or delayed healing after dental work, persistent jaw pain or swelling, trismus
AmputationAmputation-related complications (impaired cosmesis, functional/activity limitations, residual limb integrity, chronic pain, increased energy expenditure)History: pain, functional/activity limitations
Exam: residual limb integrity
Prosthetic evaluation
Limb-sparing surgeryLimb-sparing surgical complications (functional/activity limitations, fibrosis, contractures, chronic infection, chronic pain, limb length discrepancy, increased energy expenditure, prosthetic malfunction [loosening, non-union, fracture])History: pain, functional/activity limitations
Exam: residual limb integrity
Radiograph of affected limb
Orthopedic evaluation
HSCT with any history of chronic GVHDJoint contractureMusculoskeletal exam
Refer to the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers for musculoskeletal system late effects information, including risk factors, evaluation, and health counseling.
References
  1. Green DM: 11th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer. Forward. Pediatr Blood Cancer 58 (1): 111, 2012. [PUBMED Abstract]
  2. Hudson MM, Neglia JP, Woods WG, et al.: Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer 58 (3): 334-43, 2012. [PUBMED Abstract]
  3. Estilo CL, Huryn JM, Kraus DH, et al.: Effects of therapy on dentofacial development in long-term survivors of head and neck rhabdomyosarcoma: the memorial sloan-kettering cancer center experience. J Pediatr Hematol Oncol 25 (3): 215-22, 2003. [PUBMED Abstract]
  4. Gevorgyan A, La Scala GC, Neligan PC, et al.: Radiation-induced craniofacial bone growth disturbances. J Craniofac Surg 18 (5): 1001-7, 2007. [PUBMED Abstract]
  5. Karsila-Tenovuo S, Jahnukainen K, Peltomäki T, et al.: Disturbances in craniofacial morphology in children treated for solid tumors. Oral Oncol 37 (7): 586-92, 2001. [PUBMED Abstract]
  6. Paulino AC, Simon JH, Zhen W, et al.: Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 48 (5): 1489-95, 2000. [PUBMED Abstract]
  7. Choi SY, Kim MS, Yoo S, et al.: Long term follow-up results of external beam radiotherapy as primary treatment for retinoblastoma. J Korean Med Sci 25 (4): 546-51, 2010. [PUBMED Abstract]
  8. Raney RB, Anderson JR, Kollath J, et al.: Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991. Med Pediatr Oncol 34 (6): 413-20, 2000. [PUBMED Abstract]
  9. Shildkrot Y, Kirzhner M, Haik BG, et al.: The effect of cancer therapies on pediatric anophthalmic sockets. Ophthalmology 118 (12): 2480-6, 2011. [PUBMED Abstract]
  10. Sklar CA, Constine LS: Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiat Oncol Biol Phys 31 (5): 1113-21, 1995. [PUBMED Abstract]
  11. Brownstein CM, Mertens AC, Mitby PA, et al.: Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 89 (9): 4422-7, 2004. [PUBMED Abstract]
  12. Kiehna EN, Merchant TE: Radiation therapy for pediatric craniopharyngioma. Neurosurg Focus 28 (4): E10, 2010. [PUBMED Abstract]
  13. Nandagopal R, Laverdière C, Mulrooney D, et al.: Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 69 (2): 65-74, 2008. [PUBMED Abstract]
  14. Packer RJ, Boyett JM, Janss AJ, et al.: Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 19 (2): 480-7, 2001. [PUBMED Abstract]
  15. Chow EJ, Friedman DL, Yasui Y, et al.: Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr 150 (4): 370-5, 375.e1, 2007. [PUBMED Abstract]
  16. Sklar C, Mertens A, Walter A, et al.: Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr 123 (1): 59-64, 1993. [PUBMED Abstract]
  17. Bongers ME, Francken AB, Rouwé C, et al.: Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation. Pediatr Blood Cancer 45 (2): 139-43, 2005. [PUBMED Abstract]
  18. Huma Z, Boulad F, Black P, et al.: Growth in children after bone marrow transplantation for acute leukemia. Blood 86 (2): 819-24, 1995. [PUBMED Abstract]
  19. Leung W, Ahn H, Rose SR, et al.: A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) 86 (4): 215-24, 2007. [PUBMED Abstract]
  20. Sanders JE: Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant 41 (2): 223-7, 2008. [PUBMED Abstract]
  21. Sanders JE, Guthrie KA, Hoffmeister PA, et al.: Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 105 (3): 1348-54, 2005. [PUBMED Abstract]
  22. Shalitin S, Laur E, Lebenthal Y, et al.: Endocrine complications and components of the metabolic syndrome in survivors of childhood malignant non-brain solid tumors. Horm Res Paediatr 81 (1): 32-42, 2014. [PUBMED Abstract]
  23. Fletcher BD: Effects of pediatric cancer therapy on the musculoskeletal system. Pediatr Radiol 27 (8): 623-36, 1997. [PUBMED Abstract]
  24. Hogeboom CJ, Grosser SC, Guthrie KA, et al.: Stature loss following treatment for Wilms tumor. Med Pediatr Oncol 36 (2): 295-304, 2001. [PUBMED Abstract]
  25. Merchant TE, Nguyen L, Nguyen D, et al.: Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. Int J Radiat Oncol Biol Phys 59 (2): 556-61, 2004. [PUBMED Abstract]
  26. Willman KY, Cox RS, Donaldson SS: Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 28 (1): 85-92, 1994. [PUBMED Abstract]
  27. Wallace WH, Shalet SM, Morris-Jones PH, et al.: Effect of abdominal irradiation on growth in boys treated for a Wilms' tumor. Med Pediatr Oncol 18 (6): 441-6, 1990. [PUBMED Abstract]
  28. Silber JH, Littman PS, Meadows AT: Stature loss following skeletal irradiation for childhood cancer. J Clin Oncol 8 (2): 304-12, 1990. [PUBMED Abstract]
  29. Hartley KA, Li C, Laningham FH, et al.: Vertebral body growth after craniospinal irradiation. Int J Radiat Oncol Biol Phys 70 (5): 1343-9, 2008. [PUBMED Abstract]
  30. Paulino AC, Nguyen TX, Mai WY: An analysis of primary site control and late effects according to local control modality in non-metastatic Ewing sarcoma. Pediatr Blood Cancer 48 (4): 423-9, 2007. [PUBMED Abstract]
  31. de Jonge T, Slullitel H, Dubousset J, et al.: Late-onset spinal deformities in children treated by laminectomy and radiation therapy for malignant tumours. Eur Spine J 14 (8): 765-71, 2005. [PUBMED Abstract]
  32. Paulino AC, Wen BC, Brown CK, et al.: Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys 46 (5): 1239-46, 2000. [PUBMED Abstract]
  33. Wilson CL, Dilley K, Ness KK, et al.: Fractures among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 118 (23): 5920-8, 2012. [PUBMED Abstract]
  34. Wasilewski-Masker K, Kaste SC, Hudson MM, et al.: Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics 121 (3): e705-13, 2008. [PUBMED Abstract]
  35. Davies JH, Evans BA, Jenney ME, et al.: Skeletal morbidity in childhood acute lymphoblastic leukaemia. Clin Endocrinol (Oxf) 63 (1): 1-9, 2005. [PUBMED Abstract]
  36. van der Sluis IM, Boot AM, Hop WC, et al.: Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study. Horm Res 58 (5): 207-14, 2002. [PUBMED Abstract]
  37. van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, et al.: Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 35 (4): 415-20, 2000. [PUBMED Abstract]
  38. Gurney JG, Kaste SC, Liu W, et al.: Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 61 (7): 1270-6, 2014. [PUBMED Abstract]
  39. Siegel DA, Claridy M, Mertens A, et al.: Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors. Pediatr Blood Cancer 64 (9): , 2017. [PUBMED Abstract]
  40. Oeffinger KC, Hudson MM, Landier W: Survivorship: childhood cancer survivors. Prim Care 36 (4): 743-80, 2009. [PUBMED Abstract]
  41. van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, et al.: Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr 141 (2): 204-10, 2002. [PUBMED Abstract]
  42. Arikoski P, Komulainen J, Riikonen P, et al.: Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child 80 (2): 143-8, 1999. [PUBMED Abstract]
  43. Brennan BM, Mughal Z, Roberts SA, et al.: Bone mineral density in childhood survivors of acute lymphoblastic leukemia treated without cranial irradiation. J Clin Endocrinol Metab 90 (2): 689-94, 2005. [PUBMED Abstract]
  44. Kadan-Lottick N, Marshall JA, Barón AE, et al.: Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998. J Pediatr 138 (6): 898-904, 2001. [PUBMED Abstract]
  45. Kaste SC, Jones-Wallace D, Rose SR, et al.: Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 15 (5): 728-34, 2001. [PUBMED Abstract]
  46. Warner JT, Evans WD, Webb DK, et al.: Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res 45 (4 Pt 1): 544-51, 1999. [PUBMED Abstract]
  47. Mandel K, Atkinson S, Barr RD, et al.: Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 22 (7): 1215-21, 2004. [PUBMED Abstract]
  48. Holzer G, Krepler P, Koschat MA, et al.: Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg Br 85 (2): 231-7, 2003. [PUBMED Abstract]
  49. den Hoed MA, Klap BC, te Winkel ML, et al.: Bone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer. Osteoporos Int 26 (2): 521-9, 2015. [PUBMED Abstract]
  50. den Hoed MA, Pluijm SM, te Winkel ML, et al.: Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia. Haematologica 100 (12): 1564-70, 2015. [PUBMED Abstract]
  51. Wilson CL, Chemaitilly W, Jones KE, et al.: Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia. J Clin Oncol 34 (21): 2509-15, 2016. [PUBMED Abstract]
  52. Benmiloud S, Steffens M, Beauloye V, et al.: Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr 74 (4): 241-50, 2010. [PUBMED Abstract]
  53. McClune BL, Polgreen LE, Burmeister LA, et al.: Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant 46 (1): 1-9, 2011. [PUBMED Abstract]
  54. Le Meignen M, Auquier P, Barlogis V, et al.: Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 118 (6): 1481-9, 2011. [PUBMED Abstract]
  55. Kodama M, Komura H, Shimizu S, et al.: Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic stem cell transplantation: a longitudinal study. Fertil Steril 95 (2): 731-5, 2011. [PUBMED Abstract]
  56. Paulino AC: Late effects of radiotherapy for pediatric extremity sarcomas. Int J Radiat Oncol Biol Phys 60 (1): 265-74, 2004. [PUBMED Abstract]
  57. Wagner LM, Neel MD, Pappo AS, et al.: Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol 23 (9): 568-71, 2001. [PUBMED Abstract]
  58. Sala A, Mattano LA Jr, Barr RD: Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy. Eur J Cancer 43 (4): 683-9, 2007. [PUBMED Abstract]
  59. Elmantaser M, Stewart G, Young D, et al.: Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child 95 (10): 805-9, 2010. [PUBMED Abstract]
  60. Mattano LA Jr, Devidas M, Nachman JB, et al.: Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol 13 (9): 906-15, 2012. [PUBMED Abstract]
  61. Bürger B, Beier R, Zimmermann M, et al.: Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatr Blood Cancer 44 (3): 220-5, 2005. [PUBMED Abstract]
  62. Karimova EJ, Rai SN, Howard SC, et al.: Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol 25 (12): 1525-31, 2007. [PUBMED Abstract]
  63. Karimova EJ, Wozniak A, Wu J, et al.: How does osteonecrosis about the knee progress in young patients with leukemia?: a 2- to 7-year study. Clin Orthop Relat Res 468 (9): 2454-9, 2010. [PUBMED Abstract]
  64. Campbell S, Sun CL, Kurian S, et al.: Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer 115 (18): 4127-35, 2009. [PUBMED Abstract]
  65. Kawedia JD, Kaste SC, Pei D, et al.: Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 117 (8): 2340-7; quiz 2556, 2011. [PUBMED Abstract]
  66. Girard P, Auquier P, Barlogis V, et al.: Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood. Haematologica 98 (7): 1089-97, 2013. [PUBMED Abstract]
  67. Aricò M, Boccalatte MF, Silvestri D, et al.: Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 88 (7): 747-53, 2003. [PUBMED Abstract]
  68. Ribeiro RC, Fletcher BD, Kennedy W, et al.: Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia 15 (6): 891-7, 2001. [PUBMED Abstract]
  69. Padhye B, Dalla-Pozza L, Little D, et al.: Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL). Cancer Med 5 (5): 960-7, 2016. [PUBMED Abstract]
  70. te Winkel ML, Pieters R, Hop WC, et al.: Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol 29 (31): 4143-50, 2011. [PUBMED Abstract]
  71. Faraci M, Calevo MG, Lanino E, et al.: Osteonecrosis after allogeneic stem cell transplantation in childhood. A case-control study in Italy. Haematologica 91 (8): 1096-9, 2006. [PUBMED Abstract]
  72. Relling MV, Yang W, Das S, et al.: Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 22 (19): 3930-6, 2004. [PUBMED Abstract]
  73. Vrooman LM, Stevenson KE, Supko JG, et al.: Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 31 (9): 1202-10, 2013. [PUBMED Abstract]
  74. Hyakuna N, Shimomura Y, Watanabe A, et al.: Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. J Pediatr Hematol Oncol 36 (1): 22-9, 2014. [PUBMED Abstract]
  75. Yang L, Panetta JC, Cai X, et al.: Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 26 (12): 1932-9, 2008. [PUBMED Abstract]
  76. Badhiwala JH, Nayiager T, Athale UH: The development of thromboembolism may increase the risk of osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 62 (10): 1851-4, 2015. [PUBMED Abstract]
  77. Li X, Brazauskas R, Wang Z, et al.: Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant 20 (4): 587-92, 2014. [PUBMED Abstract]
  78. Mattano LA Jr, Sather HN, Trigg ME, et al.: Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 18 (18): 3262-72, 2000. [PUBMED Abstract]
  79. Karol SE, Mattano LA Jr, Yang W, et al.: Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood 127 (5): 558-64, 2016. [PUBMED Abstract]
  80. Finkelstein Y, Blonquist TM, Vijayanathan V, et al.: A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 64 (7): , 2017. [PUBMED Abstract]
  81. Karol SE, Yang W, Van Driest SL, et al.: Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood 126 (15): 1770-6, 2015. [PUBMED Abstract]
  82. Bovée JV: Multiple osteochondromas. Orphanet J Rare Dis 3: 3, 2008. [PUBMED Abstract]
  83. Danner-Koptik K, Kletzel M, Dilley KJ: Exostoses as a long-term sequela after pediatric hematopoietic progenitor cell transplantation: potential causes and increase risk of secondary malignancies from Ann & Robert H. Lurie Children's Hospital of Chicago. Biol Blood Marrow Transplant 19 (8): 1267-70, 2013. [PUBMED Abstract]
  84. Faraci M, Bagnasco F, Corti P, et al.: Osteochondroma after hematopoietic stem cell transplantation in childhood. An Italian study on behalf of the AIEOP-HSCT group. Biol Blood Marrow Transplant 15 (10): 1271-6, 2009. [PUBMED Abstract]
  85. Kushner BH, Roberts SS, Friedman DN, et al.: Osteochondroma in long-term survivors of high-risk neuroblastoma. Cancer 121 (12): 2090-6, 2015. [PUBMED Abstract]
  86. Bordigoni P, Turello R, Clement L, et al.: Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases. Bone Marrow Transplant 29 (7): 611-4, 2002. [PUBMED Abstract]
  87. Taitz J, Cohn RJ, White L, et al.: Osteochondroma after total body irradiation: an age-related complication. Pediatr Blood Cancer 42 (3): 225-9, 2004. [PUBMED Abstract]
  88. King EA, Hanauer DA, Choi SW, et al.: Osteochondromas after radiation for pediatric malignancies: a role for expanded counseling for skeletal side effects. J Pediatr Orthop 34 (3): 331-5, 2014 Apr-May. [PUBMED Abstract]
  89. Nagarajan R, Neglia JP, Clohisy DR, et al.: Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol 20 (22): 4493-501, 2002. [PUBMED Abstract]
  90. Aulivola B, Hile CN, Hamdan AD, et al.: Major lower extremity amputation: outcome of a modern series. Arch Surg 139 (4): 395-9; discussion 399, 2004. [PUBMED Abstract]
  91. Kaste SC, Neel MN, Rao BN, et al.: Complications of limb-sparing procedures using endoprosthetic replacements about the knee for pediatric skeletal sarcomas. Pediatr Radiol 31 (2): 62-71, 2001. [PUBMED Abstract]
  92. Eiser C, Darlington AS, Stride CB, et al.: Quality of life implications as a consequence of surgery: limb salvage, primary and secondary amputation. Sarcoma 5 (4): 189-95, 2001. [PUBMED Abstract]
  93. Renard AJ, Veth RP, Schreuder HW, et al.: Function and complications after ablative and limb-salvage therapy in lower extremity sarcoma of bone. J Surg Oncol 73 (4): 198-205, 2000. [PUBMED Abstract]
  94. Fernandez-Pineda I, Hudson MM, Pappo AS, et al.: Long-term functional outcomes and quality of life in adult survivors of childhood extremity sarcomas: a report from the St. Jude Lifetime Cohort Study. J Cancer Surviv 11 (1): 1-12, 2017. [PUBMED Abstract]
  95. Marina N, Hudson MM, Jones KE, et al.: Changes in health status among aging survivors of pediatric upper and lower extremity sarcoma: a report from the childhood cancer survivor study. Arch Phys Med Rehabil 94 (6): 1062-73, 2013. [PUBMED Abstract]
  96. Antin JH: Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med 347 (1): 36-42, 2002. [PUBMED Abstract]
  97. Beredjiklian PK, Drummond DS, Dormans JP, et al.: Orthopaedic manifestations of chronic graft-versus-host disease. J Pediatr Orthop 18 (5): 572-5, 1998 Sep-Oct. [PUBMED Abstract]
  98. Inamoto Y, Storer BE, Petersdorf EW, et al.: Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 121 (25): 5098-103, 2013. [PUBMED Abstract]
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)